ARIA - ARIAD Pharmaceuticals

[affoxBABisona]

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

http://finviz.com/chart.ashx?t=ARIA&ty=c&ta=1&p=d&s=l

[AgustinKasp]

$8 resistance holding

[ahonepewafafo]

Yep, we need a breakout at that level.

[Akinozilkreeel]

Big mover!

+9% today!

[AlaloLoagNany]

CAMBRIDGE, Mass.--(BUSINESS WIRE)--


ARIAD Pharmaceuticals, Inc. (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ariad.com%2F&esheet=51351827&newsitemid=20160531005383&lan=en-US&anchor=ARIAD+Pharmaceuticals%2C+Inc.&index=1&md5=3eed320764cd3f6f81a8920cdaa682bb) (ARIA (http://finance.yahoo.com/q?s=aria)) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2. AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately four to nine percent of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.1 Additionally, approximately two percent of NSCLC patients2 have HER2 mutations, with the majority having exon 20 insertion mutations.